Hepatitis B Interventions in East- and Southeast-Asian Communities in the U.S. by Menninga, Alizarin
Tapestries: Interwoven voices of local and global identities
Volume 4
Issue 1 Threats to the American Dream Article 12
2015
Hepatitis B Interventions in East- and Southeast-
Asian Communities in the U.S.
Alizarin Menninga
Macalester College, amenning@macalester.edu
Follow this and additional works at: http://digitalcommons.macalester.edu/tapestries
This Structural Healing: Impacts of Racism on Health is brought to you for free and open access by the American Studies Department at
DigitalCommons@Macalester College. It has been accepted for inclusion in Tapestries: Interwoven voices of local and global identities by an
authorized administrator of DigitalCommons@Macalester College. For more information, please contact scholarpub@macalester.edu.
Recommended Citation
Menninga, Alizarin (2015) "Hepatitis B Interventions in East- and Southeast-Asian Communities in the U.S.," Tapestries: Interwoven
voices of local and global identities: Vol. 4: Iss. 1, Article 12.
Available at: http://digitalcommons.macalester.edu/tapestries/vol4/iss1/12
Alizarin Menninga
Hepatitis B Interventions in East- and Southeast-Asian Communities 
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Preface 
 After reading scholar Alondra Nelson’s Body 
and Soul: The Black Panther Party and the Fight Against 
Medical Discrimination, a book that focuses on the 
link between sickle cell anemia and the political 
resistance to community-based health initiatives, I 
became interested in other diseases that are cultur-
ally, racially, and ethnically specific. I realized with-
in my own community that hepatitis B is common. 
Both my mother and grandmother have had hep-
atitis B. As a Biology major and an American Stud-
ies major, I have sought ways to challenge racial 
injustices in health and medicine in the U.S. I present 
that Asian American and Pacific-Asian communities 
in the U.S. have specific needs to be addressed in 
the prevention and treatment of hepatitis B. In this 
paper I encourage an openness to the question: Can 
there be a disciplinary focus on this intersection 
from elementary education to med school? 
As noted, this paper seeks to delve into 
the study of Asian Americans’ relationship with 
hepatitis B. I reference medical vulnerability in 
relation to white males because the health field is 
largely comprised of and bases their information 
on this group. However, “Asian American” is an 
incredibly broad term that encompasses people from 
Pakistan to Korea, and from recent migrants to 
people whose families have been in the U.S. since 
the 1800s. In the introduction to The Very Inside: 
An Anthology of Writing by Asian and Pacific Islander 
Lesbian and Bixesual Women, Sharon Lim-Hing 
describes how the term “Asian” signifies groups 
of people from South Asia or East Asia, two very 
different cultures, depending on context [1]. In 
essence, it is important to name where specifical-
ly and regionally these people have their origins. 
She says, “In Canada, “Asian” has come to mean 
East Asian, and South Asians must struggle against 
invisibility” [1]. By not specifically naming origins, 
some feel marginalized and their culture is seen as 
invisible.  
In my research on hepatitis B, I encoun-
tered resources for “Asian American and Pacific 
Islanders” or “API” with hepatitis B [2]. However, I 
did not encounter any research on hepatitis B that 
included “indigenous Samoans, Fijians, Hawaiians, 
Guamanians, or Polynesians” [1]. Though “Asians” 
and “Pacific Islanders” have been grouped togeth-
er since 1990 for political simplicity, it is important 
not to essentialize vastly different groups of people. 
In the research I conducted for this paper, authors 
universally used the term “Asian American” to refer 
to foreign-born Asian people who have migrated to 
the U.S. I, however, will be adopting Nilda Rimon-
te’s term “Pacific-Asian” to refer to people who 
speak an Asian language, carry epistemologies of 
Asian cultures, and are often foreign-born. I will use 
“Asian-American” to refer to Asian-heritage people 
who have grown up “American” [3]. In cases where 
the source from which I retrieved the information 
renders the distinction indistinguishable, I leave the 
term “Asian.”
Acronym Glossary:
HBV  Hepatitis B virus
CHB  Chronic hepatitis B
HCC  Hepatocellular carcinoma
SFHBFC San Francisco Hep B Free Campaign
Introduction
Over 350 million people are infected with 
CHB worldwide [9], and over seventy-five percent 
of these hepatitis B virus (HBV)-infected people are 
Pacific-Asian [10]. Over 2 million people in the U.S. 
Figure 1. Worldwide CHB prevalence from 
2005. From the CDC [49]: “Prevalence of chronic 
hepatitis B virus infection among adults in 2005”.
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are living with chronic hepatitis B, with Pacific-Asians 
accounting for half of these cases [16] [17]. Though 
less than 1% of the general U.S. population is 
positive for the hepatitis B antigen (testing anti-
gen-positive indicates HBV infection), 7-14% of 
Vietnamese Americans, 9-14% of Chinese American 
immigrants, and up to 28% of Laotian and Hmong 
American young adults are HBV antigen-positive 
[10]. Particularly, Vietnamese American males have 
eleven times the risk of developing hepatocellu-
lar carcinoma--the cancer associated with untreat-
ed chronic hepatitis B infection--than that of white 
American males [9]. A study of Chicago’s Chinatown 
found that 11.1% of Chinese Americans were HBV 
carriers [18].
Untreated actively replicating HBV can 
develop into liver cancer. In the U.S., cancer is re-
sponsible for 1 in 4 deaths [11]. Liver cancer ranks 
among the top fourth of lethal cancers for Asian/Pa-
cific Islander males, and the top seventh for Black, 
American Indian/Alaska Native, and Hispanic males 
[12]. Fifteen to twenty percent of people with ac-
tively replicating HBV will develop cirrhosis within 
five years, increasing chances of the disease evolv-
ing into hepatocellular carcinoma (HCC) given that 
70-90% of HCC patients have cirrhosis (scarring of 
the liver in late stage liver disease) [13]. People with 
CHB have a risk of 15-25% throughout their lives of 
death from HCC [14]. About 500,000 people world-
wide die from cirrhosis and HCC annually due to 
chronic infection; about 40,000 more people die an-
nually of acute hepatitis B [15].
HCC is one of the fastest growing cancers 
in the U.S., and is the second most deadly cancer 
determined by survival time [14]. While non-Latino 
white males had an incidence of 3.3 per 100,000 for 
liver cancer by 1992, Korean American males expe-
rienced rates of 24.8 per 100,000, and Vietnamese 
Americans at 41.8 per 100,000 [10]. Forty percent 
of Asian males with CHB die of cirrhosis compli-
cations or HCC [13]. However, up to two thirds of 
people with CHB may not know that they are HBV 
positive [9]. This discrepancy is further exacerbated 
as 60% of CHB patients report being asymptomat-
ic [14]. These statistics alone show that there is a 
need to understand the disease and its effects on 
the Asian-American and Pacific-Asian communities. 
Hepatitis B can be differentiated from other 
types of hepatitis by its prevalence, modes of trans-
mission, late-stage manifestation, prevention, and 
treatment (Table 1). There are five different hepati-
tis viruses from different taxonomic families, which 
primarily replicate in the liver [4]. Three of these vi-
ruses--hepatitis B, C, and delta viruses--are primarily 
transmitted through blood and other bodily fluids 
[4]. Hepatitis A and E viruses are often fecally trans-
mitted [4]. In 2012, there were an estimated 3,050 
cases of acute hepatitis A virus infection, 18,760 
acute hepatitis B cases, and an estimated 21,870 
acute cases of hepatitis C in the United States [5]. 
Hepatitis B stands out as the leading cause world-
wide of liver failure and liver cancer [6]. Hepatitis 
A is also a contagious liver infection, but does not 
cause chronic infection like HBV.
The outcome of an HBV infection is deter-
mined by an individual’s immune response. In most 
cases of adult exposure to hepatitis B, the immune 
system will eradicate the virus without treatment 
and result in immunity to the virus [7]. However, a 
small portion—about 2%—of infected people be-
come virus carriers [8]. If the immune system re-
sponse is not sufficient and the virus resides in the 
infected individual for over six months, the person 
is considered to have chronic hepatitis B (CHB). 
 
Nature of Viral Infection
The hepatitis B virus enacts its pathology 
when it infects liver cells [19]. Its genomic DNA en-
ters the liver cell’s nucleus through pores, where it 
is converted into covalently closed circular DNA 
(cccDNA). In the nucleus, this cccDNA is transcribed 
into many viral mRNAs. Upon leaving the nucleus for 
the cytoplasm, these mRNAs are either translated 
into viral proteins or packed into nucleocapsids to 
be converted back into viral DNA. This new capsule 
of HBV then is released out of the cell, along with 
hepatitis B surface protein (Figure 2). This protein is 
detectable as HBsAg in the serum in acute or chron-
ic infection; its detection is used as a diagnostic tool. 
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Basis for Diagnosis
Virus Transmission causes Symptoms 
Hepatitis A 
Single-stranded RNA 
• Fecal-oral 
• Contact more intimate than 
“casual” with infectious 
person 
• Fever 
• Malaise 
• Appetite loss 
• Diarrhea 
• Nausea 
• Abdominal discomfort 
• Dark-colored urine 
• Jaundice 
Hepatitis B 
Partially double-
stranded DNA 
• Bodily fluid contact Vertical 
transmission 
• Household and sexual contact 
• Subcutaneous needle use 
• Jaundice 
• Dark-colored urine 
• Fatigue 
• Nausea 
• Vomiting 
• Abdominal pain 
• Chronic liver infection resulting in cirrhosis 
or cancer 
Hepatitis C 
Single-stranded RNA 
• Unsafe drug injection 
• Inadequate sterilization of 
medical equipment 
• Unscreened blood 
• Less common: Sexual and 
vertical transmission 
• Fever 
• Fatigue 
• Appetite loss 
• Nausea 
• Vomiting 
• Abdominal pain 
• Dark-colored urine 
• Grey-colored feces 
• Joint pain 
• Jaundice 
• Chronic liver infection leading to cirrhosis 
or cancer 
Hepatitis D 
(delta hepatitis) 
Single-stranded 
circular RNA 
 
• Occurs among people already 
infected with HBV 
• Blood contact 
• Greater risk of liver failure 
• Quicker progression to cirrhosis 
• Increased chances of liver cancer 
Hepatitis E 
Single-stranded RNA 
• Fecal-oral (drinking water) 
• Infected blood transfusion 
• Vertical transmission 
• Jaundice 
• Appetite loss 
• Hepatomegaly 
• Abdominal pain 
• Nausea 
• Vomiting 
• Fever 
• Risk of obstetrical complications 
• Occasionally leads to liver failure 
	  
Table 1. Comparative transmissions and symptoms of the five types of hepatitis. Information from 
the WHO [50].
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Figure 2. HBV life-cycle. Figure taken from Urban et al. [19]: “The replication cycle of hepatitis B virus”.
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Positive hepatitis B status is determined by 
the presence of HBsAg in the serum of an infected 
person, which can be detected in high levels [20]. 
The hepatitis B e Antigen (HBeAg) is secreted by 
the nucleocapsid HBV gene, and is a marker of vi-
ral replication that indicates high levels of HBV. Pa-
tients are determined to have chronic hepatitis B 
when they test positive for the HBsAg virus anti-
gen for over six consecutive months. In HBV cases, 
seroconversion refers to when a patient yields an 
HBeAg-positive response to testing, and responds 
to HBeAg-positive CHB treatment [21]. The medi-
an age of seroconversion in Pacific-Asian patients—
who are primarily infected at birth—is about 35 years 
old [21]. Seroconversion happens spontaneously at 
about 5-10% per year once a person is infected with 
the virus [21]. 
Among other viral markers, serum levels of 
both HBV DNA and HBsAg rise in cases of CHB [19]. 
The HBsAg level is an important diagnostic param-
eter of HBV positivity. Persistent HBsAg levels are 
associated with increased risk of HCC. 
The increase of serum alanine aminotrans-
ferase (ALT) after HBeAg seroconversion increas-
es the risk of cirrhosis and HCC [13]. Ninety per-
cent of neonatal HBV infections and 25-50% of 
infections in young children who were infected 
when they were infants develop into chronic hep-
atitis B [9]. People with acute hepatitis B can pres-
ent with nausea, abdominal pain, and jaundice. 
However, they may also be asymptomatic—es-
pecially when they are infants and children [10]. 
 
Transmission
HBV is transmitted through contact with tis-
sues deeper than the skin of an uninfected person 
with infectious blood or body fluids. Examples of 
contagious events include sexual intercourse with 
infected persons, intravenous use with an infected 
needle, and childbirth from an HBV-positive moth-
er. HBV can also be transmitted through sharing 
semi-invasive utensils such as over-filing at nail sa-
lons [22].
HBV is transmitted horizontally through sex-
ual contact, blood transfusion, medical utensils, and 
personal-use objects like razors and toothbrushes 
[10]. For Pacific-Asian people, transmission most com-
monly occurs vertically from a mother to their baby 
at childbirth or is acquired at a young age [10] [16]. 
Vertical transmission can occur both through the pla-
centa and during the act of childbirth [23]. Overall, the 
risk for transmission to family members is high [24]. 
 
Screening
HBV screening is recommended for people 
of all walks of life, particularly all pregnant people 
Table 2. Additional 
Uses of HBV Antivi-
rals. From University 
of Washington [51]: 
“Antiviral Agents with 
Activity Against HBV 
and HIV”.
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and foreign-born people from areas endemic with 
hepatitis B [10]. Hepatitis B screening and diagno-
sis can lead HBV+ people to receive antiviral thera-
pies and decrease their chances of developing HCC 
[9]. However, physicians who serve Pacific-Asian 
communities have reported reluctance to conduct 
HBV screening because their patients may be cul-
turally or financially prevented from seeking treat-
ment [11]. A survey of Chinese females in Seattle 
found that only 35% had been screened for HBV, 
though they are part of a high-risk population [6]. 
Ma et al. completed a study in which they surveyed 
over 2,000 Pacific-Asians from the East Coast. They 
found that those who believed they had agency to 
prevent cancer and those who used the internet 
are more likely to get screened for hepatitis B [25]. 
This study demonstrates that prevention awareness 
leads people to seek HBV screening. Furthermore, 
a study of Asian versus white American patients in 
San Francisco demonstrated that in most instances, 
Asian ethnic groups are significantly more likely to 
be screened for HBV. The figures show that 65% 
of Chinese-speaking Chinese patients are screened, 
while only 21% of white Americans are screened [6]. 
Though it seems as if this discrepancy is a positive 
indicator with at-risk communities being screened 
more than others, it still follows that this is not a rate 
of 100% and that Chinese-speaking patients for the 
most part are not screened enough. 
HBV can be prevented with a vaccination. 
HBV vaccination is universally recommended in the 
U.S. for children zero to eighteen-years-old, health 
care workers, dialysis patients, people with multiple 
sex partners, injection drug users, men who have sex 
with men, and sexual/household partners of people 
with hepatitis B. Interestingly, it is the only vaccina-
tion administered to newborns (compared with the 
hepatitis A vaccine which can only be administered 
to children when they are older than 12 months old) 
since the virus can linger in newborns and manifest 
in lifelong chronic illness [26]. The vaccine has a 95% 
prevention efficacy rate [27].  
The low rate of Asian American vaccination 
is due to particular barriers. One study gathered in-
formation from a diverse group of Asian Americans 
that showed that few family members encouraged 
one another to get vaccinated or tested [28]. Another 
study proposed that barriers to vaccination among 
Chinese in New York City included not having the 
time to seek vaccinations, not knowing where to 
get screened, not having a primary care provider, 
and not speaking the same language as their phy-
sician [29]. However, a study of Chinese Americans 
in Chicago found that nearly all respondents under-
stood that HBV is preventable by vaccination, and 
having a primary care physician led Chinese pa-
tients to have higher rates of vaccination [18] [29]. 
 
Treatment
Ninety-five percent of infected adults and 
older children can become hepatitis B-immune af-
ter clearing the infection from their system without 
treatment [9]. Those who do not clear the virus af-
ter six or more months of acute hepatitis B develop 
chronic hepatitis B, an incurable condition. However, 
there are pharmaceutical treatments that slow viral 
replication and thus disease progression, including 
Interferon-alpha, Lamivudine, and Adefovir dipiv-
oxil. Antiviral treatments suppress HBV and reduce 
hepatic inflammatory response in HCC as well as 
necroinflammatory activity in CHB. Lowering the 
quantity of virus in an infected person’s system can 
prevent cirrhosis, liver failure, and HCC [35] [13].
Clearing detectable HBsAg and/or serocon-
version is the closest to a cure that currently exists 
in the treatment of hepatitis B [30]. Currently, there 
are seven different FDA-approved antivirals to treat 
CHB [31]. These antivirals are interferon-alpha, pe-
gylated interferon-alpha, lamivudine, adefovir (dipiv-
oxil), entecavir, telbivudine and tenofovir (disoproxil 
fumarate) (Table 2) [47]. These antiviral treatments, 
however, are prescribed to fewer than 50,000 peo-
ple per year, or less than 2.5% of estimated cases 
in the U.S. [14]. Long-term entecavir treatment has 
shown improved liver histology in Asian American 
patients [32]. Both entecavir and tenofovir could be 
effective medications for “Asians” because of their 
low reported side effects—including liver disease 
development—and high safety ratings, but due to 
their underutilized nature, they are not supplied as 
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often as they should be [33]. 
Another antiviral treatment is lamivudine. 
This is an oral antiviral treatment that suppresses 
the virus, reduces necroinflammatory activity, and 
improves liver fibrosis histology and liver function 
[13]. Side effects such as viral resistance can devel-
op from lamivudine use. Hepatitis flares can arise 
resulting in liver failure and death, and decrease in 
liver function leading to decompensation or cirrho-
sis [13].
Like most viruses, there are practice guide-
lines that determine a subset of patients who can 
receive treatment for CHB. This group of people 
generally includes those with biochemical and histo-
logical markers of moderate to severe liver disease 
[34]. However, official guidelines are changing as 
people with higher potential risk factors become in-
creasingly illuminated through research. Additional-
ly, people whose infections progress rapidly can be 
eligible for treatment [14]. Even given the changes 
to the scope of those treated, Pacific-Asian people 
who are not fluent in English have a lower chance 
of receiving adequate treatment [6]. Pacific-Asian 
patients have barriers beyond language, including 
financial cost and reported side effects (liver and 
bone-density damage) when given the treatment 
[16]. Consequently, HBV+ Asian Americans who are 
English speakers and thus can better communicate 
with their physicians to learn about effective anti-
viral treatment often do not utilize the service be-
cause of their fears of the treatments’ side effects 
[16]. Although both of these groups have similar 
concerns, there are also discrepancies in treatment 
of foreign-born and U.S.-born Asian people in the 
U.S. Carabez et al. performed a study showing that 
70% of U.S.-born HBV+ respondents were receiving 
treatment, with 90% having received prior treatment. 
Less than 40% of foreign-born HBV-infected Pacif-
ic-Asians of the same study were receiving treatment 
at the time of survey, and only 50% had received past 
treatment [28]. Additionally, health care providers re-
ported immunizing and screening people who could 
afford the cost of care, at the risk of missing HBV+ 
people who could not afford all screening tests [22]. 
 
Cultural Responses
There are no studies that look at disparities 
in initiation of antiviral therapy and therapy comple-
tion in HBV+ Pacific-Asians or Asian Americans [28]. 
However, surveyed health practitioners reported a 
list of cultural reasonings that affect treatment for 
Pacific-Asian and Asian Americans. First, a Hwang 
et al. study of Chinese, Korean, and Vietnamese 
communities in Houston noted doubts about Pacif-
ic-Asians following through with their prescribed 
HBV treatments [22]. Some Pacific-Asian patients 
have been reported to not return to a clinic after 
being diagnosed with HBV, as they do not always 
understand what the doctor is telling them about 
hepatitis [22]. However, their choice not to return 
to their physicians may stem from their reluctance 
to disagree or argue with a physician. This can re-
sult in them not taking medications as prescribed 
[25]. Secondly, in a study of Vietnamese people in 
Seattle to identify Vietnamese cultural, historical, 
and sociopolitical contexts for knowledge of HBV, 
Burke et al. situated Vietnamese communities’ un-
derstandings in histories of arriving in the U.S. as 
refugees and receiving much poorer health-care 
than white Americans [48]. Participants stated be-
liefs linking energy balance to good health, and thus 
imbalance to susceptibility to liver illness. Many re-
spondents also associated diet, strength, blood and 
energy circulation, and peace of mind with internal 
disorder-prevention including liver disease. 
Finally, complementary and alternative 
medicine (CAM) is an important cultural factor 
that determines treatment adherence and effica-
cy. These practices include acupuncture, vitamins, 
energy medicine, and herbs. Medical practitioners 
that serve Pacific-Asian communities observed 
that their patients are not able to afford antiviral 
treatment for HBV, but that CAM is inexpensive, 
available, and culturally sanctioned [22]. Though 
physicians have been known to be wary of CAM, 
believing that some may interfere with allopathic 
treatments, some feel they must show respect for 
CAM to validate their patients’ cultural backgrounds 
and beliefs. Even when CAM was not prescribed, 
Tokes et al. found that Chinese, Korean, and Viet-
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namese communities of New York metropolitan, 
San Francisco/Bay, and Los Angeles/Orange Coun-
ty areas reported treating their CHB with lifestyle 
and diet changes because of the fear of possible 
side effects from pharmaceutical treatments [16]. 
Though 88% of their respondents understood that 
CHB could cause liver damage, over a third stat-
ed reluctance to being on long-term pharmaceu-
tical therapy due to concerned over side effects. 
 
Stigma
There is a stigma associated with HBV that 
stems from white supremacy, xenophobia, and 
essentialization. Stigma has been defined as “an 
adverse social judgment resulting in exclusion, re-
jection, blame or devaluation. Stigma can damage 
self-esteem, adversely affect family members and 
social and economic status, and can lead to discrim-
ination and self-discrimination” [36]. People who are 
stigmatized in any way are generally disempowered 
from defending themselves. Power structures that 
dictate norms in our society use stigmatized differ-
ences to render people with these differences less-
er in value [37]. Thus, any resistance against stigma 
is a form of resistance against the power structures 
that create hierarchies of worth. 
Lai et al.’s study found that medical health 
professionals incorrectly associated HBV with 
HIV+ people, men who have sex with men, and in-
travenous drug users—even when they knew that 
people from China are at greater risk than white 
Americans for contracting HBV [6]. These different 
assumptions that are related only because they are 
elevated risk statuses for HBV inherently associate 
Chinese people with traits that are stigmatized in 
both U.S. and Chinese society, and further essential-
ize Chinese (and other East Asian peoples who are 
often confused with Chinese) people with societal-
ly-deemed deviant behavior. Specifically concerning 
higher-risk communities of color, like Pacific-Asians 
in the United States, breaking the stigma is a step 
against racial oppression and xenophobia. There is a 
high mental stress burden for individuals with HBV, 
no doubt contributable in part to community stigma 
[38].
Within the Asian American community, stig-
ma surrounding HBV has been generated by fear of 
contagion. Over 60% of surveyed Chinese Ameri-
cans in Chicago believed that HBV carriers put oth-
ers at risk and should subsequently avoid contact 
with others [18]. Over a third of Chinese American 
respondents stated that HBV carriers perceive that 
they bring trouble to their families, and a fifth of re-
spondents believed HBV carriers may bring harm to 
others [18]. Additionally, over 20% of respondents in 
the same study indicated that HBV carriers may be 
discriminated against in professional and academic 
settings both in China and in the U.S. [18]. A study of 
HBV+ university students in Taiwan demonstrated 
that 70% of survey respondents were afraid to tell 
their friends that they were carriers [39]. About 70% 
were also afraid of contracting HBV from a friend 
carrier [18]. A survey of HBV+ Chinese immigrants 
in Canada found that about a third were ashamed 
about having HBV, and over half would not discuss 
their infection with family and friends [40]. 
Stigma is lowered by increased knowledge 
of HBV, and being more familiar with HBV [18]. 
Researchers have found that people with a family 
member who is HBV-positive have fewer negative 
perceptions and fears of HBV contagion [18]. Un-
derstanding of stigma and fears can help determine 
appropriate interventions and educational tools to 
alleviate HBV-related stigma [18]. Furthermore, stig-
ma on the end of doctors and on the side of Asian 
American patients themselves needs to combatted. 
By disclosing HBV statuses, fear of spreading HBV 
could be erased and the stigma could be overcome 
[18]. 
Misinterpretation of HBV is attached to this 
stigma. Many researchers have studied the myths 
surrounding HBV in Pacific-Asian communities in 
the U.S. to point toward potential knowledge inter-
ventions in these high-prevalence groups. One of 
the studies led by Ma et al. found that only 23% of 
Vietnamese people in Philadelphia and New Jersey 
understood HBV could be spread through sexual in-
tercourse. Meanwhile, another study by Lee et al. 
found that only 19% of their sample of Korean im-
migrants in the Rocky Mountain area understood 
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this mode of transmissibility [44] [45]. On the con-
trast, Coronado et al. conducted a study with Chi-
nese people in Seattle which found that 65% of their 
respondees knew that HBV was preventable by vac-
cination, while a full 95% of the Chinese in Chicago 
that Cotler et al. surveyed understood this means of 
prevention [46] [18]. Similarly, only 38% of Chinese 
respondents in Seattle knew that HBV is a lifelong 
affliction, while 75% of surveyed Chinese in Chica-
go understood that HBV is a chronic infection.
Carabez et al. backed up previous studies by 
showing that gaps in information about contracting, 
transmitting, chronic infection, and prevention of 
HBV were high for foreign-born Pacific-Asians. For 
example, many do not know the difference between 
HCV and HBV [28]. In a survey of low-income Chi-
nese Americans in New York City, the majority of re-
spondents did not know that HBV could be transmit-
ted through sexual intercourse [18]. In a survey of 
Chinese Americans in Chicago, researchers found 
that the majority believed hepatitis B could be spread 
through food or eating utensils, which is untrue [18] 
(Table 1). In the same study, however, nearly all par-
ticipants understood that HBV could be spread by 
blood and in the process of childbirth. This discrepan-
cy demonstrates that some modes of transmission 
are more commonly known than others, and that 
many do not understand HBV transmission routes 
well [18]. Though these misconceptions may be ex-
emplary of white Americans as well as Asians, the U.S. 
as a whole suffers only 0.1% HBV prevalence. Asians 
in the U.S. on the other hand embody much higher 
rates, like Vietnamese American adults who suffer 
up to 14% prevalence of chronic hepatitis B [48]. 
 
Education and Resources for HBV+ Individuals
There is not enough awareness on HBV as 
it specifically affects Asian Americans, giving rise 
to a need to educate on the virus. The Hepatitis B 
Foundation exemplifies this need through publishing 
personal narratives of experiences with HBV. In one 
of their examples, a young “Asian American” doc-
tor knew he was hepatitis B positive though asymp-
tomatic [41]. When tested, medical professionals as-
sessed, due to lack of knowledge, that their patient 
would not have to be screened for liver cancer until 
he reached middle aged. “Asians,” the author broad-
ly states, have a much greater risk of developing liv-
er cancer because they are often infected early on 
in life. People infected early in life will manifest the 
cancer when the person is about 30 years of age. 
The medical practitioners based their knowledge on 
statistical experiences of white Americans, but peo-
ple whose parents are Asian immigrants are at dis-
proportionately greater risk than people of Europe-
an descent. This doctor died from liver disease in his 
early 30s because of his own and others’ unaware-
ness of differences in the manifestation of hepatitis 
B and its development into cancer for white people 
and Asian-descended people.
One way to strengthen the knowledge 
around this disease is through education. As demon-
strated in Cotler’s survey, Chinese Americans with 
higher education levels (i.e. high school graduates) 
and who spoke better English had a better under-
standing of HBV [18]. Younger respondents also 
were positively associated with having a greater 
understanding of HBV [18]. Information, education, 
and support could come from health care provid-
ers in a unique position to inform patients of fol-
low-up steps once they test positive for HBV [28]. 
Furthermore, educational campaigns launched 
through Asian-targeted community and media ven-
ues such as Asian-language newspapers, churches 
and temples, and TV and radio stations are crit-
Figure 3. San Francisco Hep B Free 2008-2009 
outreach campaign billboard. Taken from Yoo 
et al. [42]: A demonstration of the effectiveness of 
campaigns in non-English languages. 
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ical to developing culturally appropriate educa-
tion and community buy-in to HBV education [22]. 
 
Physicians 
The role of a physician is important in teach-
ing about HBV. Health care providers who have a 
better understanding of HBV generally have higher 
rates of screening their Chinese patients for HBV 
[6]. However, some physicians are unclear about dis-
ease transmission among higher risk groups, HBV’s 
natural history, its risk factors, and interpreting test 
results. Hwang et al. recommend continuing medi-
cal education to address these informational gaps 
[22]. For example, in a study of medical health prac-
titioners in San Francisco, a full 30% of survey re-
spondents did not report conducting the correct 
test to screen for HBV (HBsAg blood test for this 
antigen to the virus) [6].
Liver specialists, acupuncturists, gastroen-
terology physicians, hepatology internal medicine, 
family practice, and OB/GYNs all play a similar role 
in HBV-related diagnosis, treatment, and care for Pa-
cific-Asians and Asian Americans [22]. Pacific-Asian 
physicians are essential to providing HBV-outreach, 
education, and advocacy to communities of Asians 
in the U.S. [22]. Providers who speak an Asian lan-
guage also have higher rates of screening their 
Asian patients for HBV. Their shared background 
contributes to their understanding of the greater 
risk for HBV [6]. 
Language barriers between physicians and 
their Pacific-Asian patients must be broken down 
in order to educate about screening for the virus 
and treating/living with the virus. Without this step 
there could be an increase HBV prevalence [22]. 
Primary care physicians that serve Pacific-Asian 
and Asian American communities must also take 
patients’ concerns about side effects into account 
when counseling them on HBV treatment, com-
paring the medications’ side effects with the pos-
sibly life-threatening long-term risks of CHB [16]. 
 
Community-Based Approach
Targeted campaigns to screen and vacci-
nate Pacific-Asians and Asian Americans against 
HBV, in partnership with local health departments, 
hospitals, and community organizations, could de-
crease the HBV burden in Pacific-Asian and Asian 
American communities. Community-based screen-
ing reaches low-income and not formally- or class-
room-educated communities, people without health 
insurance, people who otherwise must surpass bar-
riers to health care providers and health systems, 
and non-English speaking communities (Figure 3) 
[9]. Community-based screening implemented in 
communities with prevalent disease stigma bypass-
es the usual inaccessibility of health care systems’ 
preventative measures [9]. The community-based 
screening measures followed in a study conducted 
by Robotin et al. included effective community en-
gagement, targeted cultural values, and low-cost or 
free follow-up and antiviral treatment for diagnosed 
HBV+ people. An example of such is the San Francis-
co Hep B Free (SFHBF) campaign. 
The goals of SFHBF included generating 
awareness among health professionals of impor-
tance about testing and vaccinating Pacific-Asians 
and -descended people against HBV, encouraging 
Figure 4. Effective strategies for health 
intervention. Lower-class, non-white communities 
need health interventions carried out in distinct ways 
from higher-class white communities. Addressing 
these differences in needs will alter future health 
interventions and assumptions about hepatitis B.
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primary care providers to conduct regular testing 
and vaccination for HBV, and guaranteeing treat-
ment for people with CHB [42]. This campaign in-
cluded media strategies which encouraged Pacif-
ic-Asians and Asian Americans to screen, vaccinate, 
and treat hep B as well as to teach and garner sup-
port from mainstream society and institutions on 
HBV [42]. The SFHBF campaign ran on volunteer 
contributions, narrative communication about HBV, 
and culturally relevant outreach to Asian communi-
ties in the U.S. [42]. In this way, the SFHBF campaign 
successfully transformed HBV from stigmatized 
and taboo to a community-wide health and well-
ness cause [42]. Through work in the media, SFHBF 
helped to alter HBV associations from misconduct 
(sexual or including drug use) and “bad people” to 
focus on medical discourse and social empower-
ment to affect change [42]. The campaign achieved 
its aims through collecting personal narratives of 
HBV from public figures like California Assembly-
woman Fiona Ma and news anchor Alan Wang [42]. 
Importantly, SFHBF focused on prevention, encour-
aged collective action, and respected the diversity 
of Asian American community and cultures [42]. 
 
Conclusion
Throughout this paper I assert that routine 
screening of all Pacific-Asians and Asian Americans 
for HBV is an indispensable measure toward fight-
ing CHB and HCC [43]. In doing so, Asian-descended 
people in the U.S. must be assessed on their health 
history on an individual national origin basis. Groups 
must be treated as hailing from different places and 
distinct cultures. Additionally, conducting a national 
study of how financial barriers affect screening and 
treatment of HBV of Pacific-Asian and Asian Amer-
ican patients could affect health policy changes to 
devote more resources to meeting the guidelines 
ascribed to these high-risk groups [22] [10]. To com-
plement screening with teaching, physicians’ treat-
ing HBV+ patients must become more educated on 
the nuances of this virus.
It is a problem that treatment and vaccina-
tion are presented and created for white Ameri-
cans with class-privileged backgrounds. Addressing 
HBV based on the protection of only one class of 
people, immigrants and non-native English speak-
ers—though they most need the interventions—are 
marginalized and do not achieve the proper inter-
ventions for hepatitis B. 
Writing on disease exclusivity and stigma, 
Parker et al. state that “the individual framework with 
which [intervention research focusing on HIV and 
AIDS-related stigmatization] operates is simply alien 
to perhaps the majority of the world’s cultures” [37]. 
This prescription of middle-class white American 
norms on all research subjects undoubtedly distorts 
and skews the goals and possible interventions that 
medicine could take towards community healing. 
Parker et al.’s critique is calling out white supremacy 
without naming it. By naming it here, I hope to be-
gin an intersectional dialogue on how to best treat 
non-upper-middle class, white, cis-gendered, En-
glish-speaking, able-bodied, heterosexual men (the 
dominant group in our society and world) as well as 
inspire truly community-based surveys that include 
narratives and testimony from affected communi-
ties on how they can be best treated.
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